Intellia Therapeutics Inc (NTLA)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES

40 ERIE STREET CAMBRIDGE, MA 02139

Intellia Therapeutics, Inc. operates as a biotechnology company. The Company focuses on the research and clinical development of gene editing therapies for patients with genetically-based diseases.

Data as of 2020-08-01
Market Cap1.045 Billion Shares Outstanding58.649 Million Avg 30-day Volume850.795 Thousand
P/E Ratio Dividend Yield EPS-2.26
Price/Sales30.304 Price cash flow ratio17.8 Price free cash flow ratio-11.2
Book Value4.22 Price to Tangible Book4.43 Alpha-0.01
Short Interest Ratio % Short Interest to Float R-squared0.134079
BETA1.61123 52-week High/Low25.56 / 9.18 Stddev0.18807
View SEC Filings from NTLA instead.
Q1 2020 All Institutions Hedge Funds 1
Filers who had this stock in their top 10: 3 1 (0.07%)
13F Filers holding this stock: 139 33 (2.16%)
Aggregate 13F shares on 03/31/2020: 46.505 Million 18.833 Million
Aggregate 13F shares on 12/31/2019: 45.603 Million 8.301 Million
Percent change: 1.98% 126.86%
Funds creating new positions: 22 6
Funds Adding to an existing position: 45 12
Funds closing out their position: 23 12
Funds reducing their position: 36 9
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding NTLA (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding NTLA BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

16.2 Thousand total shares from 3 transactions

Exercise Derivative Conversion (M)

25 Thousand total shares from 3 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

BAKER BROS. ADVISORS LP

BAKER BROS. ADVISORS (GP) LLC

BAKER FELIX

BAKER JULIAN

  • 10% Owner
0 2020-07-20 0

RIVERA JOSE E EVP, GENERAL COUNSEL

  • Officer
289,734 2020-07-15 4

LEONARD JOHN M. PRESIDENT AND CEO

  • Officer
  • Director
525,767 2020-07-01 3

KARSEN PERRY A

  • Director
0 2020-06-26 1

GORDON CARL L

  • Director
  • 10% Owner
12,714,404 2020-06-19 0

FORMELA JEAN FRANCOIS

  • Director
0 2020-06-18 1

DORSA CAROLINE

  • Director
0 2020-06-18 1

VERWIEL FRANK

  • Director
0 2020-06-18 1

GOODMAN JESSE

  • Director
0 2020-06-18 1

COHEN FRED E

  • Director
74,469 2020-06-18 1

SLAOUI MONCEF

  • Director
35,566 2020-06-11 0

LEBWOHL DAVID EVP, CHIEF MEDICAL OFFICER

  • Officer
0 2020-05-01 2

GODDARD GLENN EVP, CHIEF FINANCIAL OFFICER

  • Officer
0 2020-03-02 1

SEPP-LORENZINO LAURA EVP, CHIEF SCIENTIFIC OFFICER

  • Officer
0 2020-03-02 1

SCHIERMEIER ANDREW EVP, CHIEF OPERATING OFFICER

  • Officer
10,316 2020-01-03 1

TLS BETA PTE. LTD.

TEMASEK LIFE SCIENCES PRIVATE LTD

FULLERTON MANAGEMENT PTE LTD

TEMASEK HOLDINGS (PRIVATE) LTD

  • 10% Owner
0 2019-10-10 0

NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.

NOVARTIS AG

  • 10% Owner
4,352,295 2018-12-31 0

HAYES JOHN T. SEE REMARKS

  • Officer
0 2018-08-03 0

ATLAS VENTURE FUND IX, L.P.

ATLAS VENTURE ASSOCIATES IX, L.P.

ATLAS VENTURE ASSOCIATES IX, LLC

  • 10% Owner
4,645,453 2018-04-23 0

BELL GRAEME EVP, CHIEF FINANCIAL OFFICER

  • Officer
21,400 2018-03-28 0

CARIBOU BIOSCIENCES, INC.

No longer subject to file 2018-01-29 0

BERMINGHAM NESSAN PRESIDENT & CEO

  • Officer
  • Director
0 2017-12-12 0

ATLAS VENTURE ASSOCIATES IX, L.P.

ATLAS VENTURE ASSOCIATES IX, LLC

  • 10% Owner
3,729,788 2017-03-09 0

MORRISSEY DAVID V SVP, PLATFORM & DELIVERY TECH

  • Officer
0 2017-01-06 0

BARNES THOMAS M. SVP, R&D EXTELLIA

  • Officer
0 2017-01-06 0

HEIFNER NICOLE SVP, ACCOUNTING

  • Officer
0 2017-01-06 0

ORBIMED ADVISORS LLC

ORBIMED CAPITAL GP V LLC

ORBIMED GLOBAL HEALTHCARE GP LLC

ISALY SAMUEL D

  • Director
2,662,180 2016-05-11 0

CARIBOU THERAPEUTICS HOLDCO, LLC

CARIBOU BIOSCIENCES, INC.

  • 10% Owner
5,593,846 2016-05-11 0

HAURWITZ RACHEL E.

  • Director
  • 10% Owner
5,593,846 2016-05-11 0

FORESITE CAPITAL MANAGEMENT III, LLC

FORESITE CAPITAL FUND III, L.P.

TANANBAUM JAMES B.

  • 10% Owner
0 2016-05-05 0

SRIVASTAVA SAPNA CHIEF FINANCIAL & STATEGY OFFR

  • Officer
159,031 2016-05-05 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

RIVERA JOSE E - Officer EVP, GENERAL COUNSEL

2020-07-15 M 10,000 d 145,117 289,734.00 direct

RIVERA JOSE E - Officer EVP, GENERAL COUNSEL

2020-07-15 S 5,615 $22.70 d 27,524 289,734.00 direct yes

RIVERA JOSE E - Officer EVP, GENERAL COUNSEL

2020-07-15 M 10,000 $6.83 a 33,139 289,734.00 direct

LEONARD JOHN M. - Director - Officer PRESIDENT AND CEO

2020-07-01 M 5,000 d 340,234 525,767.00 direct

LEONARD JOHN M. - Director - Officer PRESIDENT AND CEO

2020-07-01 S 5,000 $21.83 d 467,352 525,767.00 direct yes

LEONARD JOHN M. - Director - Officer PRESIDENT AND CEO

2020-07-01 M 5,000 $6.83 a 472,352 525,767.00 direct

COHEN FRED E - Director

2020-06-18 A 19,000 a 19,000 0.00 direct

VERWIEL FRANK - Director

2020-06-18 A 19,000 a 19,000 0.00 direct

DORSA CAROLINE - Director

2020-06-18 A 19,000 a 19,000 0.00 direct

GOODMAN JESSE - Director

2020-06-18 A 19,000 a 19,000 0.00 direct

FORMELA JEAN FRANCOIS - Director

2020-06-18 A 19,000 a 19,000 0.00 direct

KARSEN PERRY A - Director

2020-06-18 A 19,000 a 19,000 0.00 direct

RIVERA JOSE E - Officer EVP, GENERAL COUNSEL

2020-06-16 M 10,000 $6.83 a 27,897 284,492.00 direct

RIVERA JOSE E - Officer EVP, GENERAL COUNSEL

2020-06-16 M 10,000 d 155,117 284,492.00 direct

RIVERA JOSE E - Officer EVP, GENERAL COUNSEL

2020-06-16 S 5,615 $21.00 d 22,282 284,492.00 direct yes
Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments